COMP <GO>
RNAZ vs ACET // FREE CASH FLOW YIELD
TransCode Therapeutics Inc. (NASDAQ) VS. Adicet Bio Inc. (NASDAQ) • 15-METRIC TALLY: RNAZ 1
— ACET 2
■ METRIC PARITY
LAST: $1.57 (-3.68%) • MKT CAP: $27.6M
fcf-yield
—
LAST: $3.17 (-0.94%) • MKT CAP: $30.0M
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RNAZ VS. ACET)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RNAZ | ACET | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | ACET | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.2 | 20.0 | +22.20 | RNAZ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.6M | $30.0M | -$2.4M | ACET | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RNAZ REV | ACET REV | RNAZ GROSS % | ACET GROSS % | RNAZ FCF | ACET FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $78.3M | $341.9M | — | — | -$19.5M | -$97.0M |
| FY 2024 | $43.8M | $357.3M | — | — | -$13.4M | -$93.5M |
| FY 2023 | $54.4M | $425.7M | — | — | -$18.1M | -$93.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RNAZ // BETA —
ACET // BETA —